StimLabs Publishes New Study Highlighting Positive Effects of Relese in Chronic Wound Healing
StimLabs® Publishes Promising Study on Relese® for Chronic Wound Treatment
StimLabs, an innovative leader in regenerative sciences, has announced the publication of its latest multicenter retrospective study. This significant research evaluates the real-world effectiveness of Relese, a fenestrated dehydrated complete human placental membrane (dCHPM) allograft, in the treatment of hard-to-heal chronic wounds. The study underlines StimLabs’ commitment to improving patient outcomes through evidence-based interventions.
Key Insights from the Study
The study’s findings are compelling. It revealed that 78% of the wounds treated with Relese achieved closure, demonstrating substantial potential for this adjunctive therapy in clinical settings. Furthermore, the median time to wound closure was recorded at 49 days, showcasing the speed at which this treatment can be effective. Additionally, the study noted an 86% mean reduction in wound area, indicating not only healing but also the overall effectiveness of the treatment protocol.
“These results bolster the argument for Relese as a valuable adjunctive treatment for various chronic wounds, including conditions such as diabetic foot ulcers and neuropathic wounds,” commented Tom Dion, Executive Vice President and Chief Commercial Officer of StimLabs.
StimLabs’ research emphasizes the growing importance of real-world data in evaluating medical treatments. By demonstrating that Relese consistently contributes to clinically meaningful wound closure across diverse clinical environments, the company underscores the relevance of human placental technologies in modern wound care strategies.
Understanding Relese
Relese operates as a fenestrated dehydrated complete human placental membrane (dCHPM) allograft. The innovative fenestration design creates a protective barrier that safeguards the wound from external elements while also enabling drainage of wound exudate. Through its patented Clearify® technology, the treatment carefully retains all three layers of the native placental membrane—amnion, intermediate layer, and chorion—alongside essential structural proteins and components crucial for healing.
About StimLabs
As a pioneering force in regenerative medicine, StimLabs focuses on addressing critical unmet needs, primarily in wound care and surgical applications. The company prides itself on its comprehensive product portfolio and its dedication to advancing safe, effective treatment options. With a strong intellectual property portfolio and a commitment to excellence, StimLabs is recognized as a trusted partner to physicians and patients alike.
By focusing on impactful solutions, StimLabs aims to change the landscape of chronic wound treatment, offering hope and healing to patients who necessitate additional support in their recovery process. This recent study serves as a testament to its mission and the innovative technologies it develops.
Conclusion
The findings from this newly published study significantly contribute to the current body of knowledge surrounding chronic wound care and highlight the importance of adjunctive therapies like Relese. As researchers continue to validate the positive outcomes from real-world applications, it’s evident that StimLabs’ commitment to enhancing patient care plays a critical role in shaping the future of treatment in regenerative medicine.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.